Global Neuroendocrine Tumor Treatment Market Analysis, Drivers, Restraints, Opportunities, Threats, Trends, Applications, and Growth Forecast to 2028
Request Covid 19 Impact
Why Choose Us
- 360 Degree Approach
- Growth Consulting
- 24/7 Research Support
- Comprehensive-Level of Customization
- Comprehensive-Level of Customization
- Competitive Intelligence
- Single-Country/ Region Intelligence
- Post-Sale Service Assistance
- Access to Lead Analysts
- Available in PDF, Excel, Word/ PPT
“Global Neuroendocrine Tumor Treatment Market Analysis Trends, Applications, Analysis, Growth, and Forecast to 2028” is a recent report generated by MarketResearch.biz. The global neuroendocrine tumor treatment market report has been segmented on the basis of drug, indication, end user, and region.
Global Neuroendocrine Tumor Treatment Market: Overview
Neuroendocrine tumors (NETs) are clinically symptomatic and asymptomatic resulting from abnormal growth of neoplasms which are originate from cells of various endocrine glands and nervous systems. Neuroendocrine tumors are generally infected in intestine – carcinoid tumors and pancreas is second most prime organ in body where growth of NET is common. Surgery is the first option for NET treatment, but as the disease is majorly asymptomatic it is diagnosed when it is in metastatic stage in that case surgery is not a feasible option.
Global Neuroendocrine Tumor Treatment Market: Dynamics
Rising prevalence of gastrointestinal and lung NET is a key factor expected to drive growth of the global market over the forecast period. In addition, increasing incidence of hormonal imbalance at pituitary gland and thyroid gland is another factor expected to further fuel growth of the target market over the forecast period.
Furthermore, increasing investment in clinical trials by major pharmaceutical companies in order to develop novel products is another factor expected to boost growth of the target market over the forecast period.
Moreover, rising adoption of advanced diagnostic imaging techniques such as endoscopic ultrasonography among users’ is another factor expected to propel growth of the global market over the forecast period.
Ongoing trend observed in the market in increasing research and development activities for neuroendocrine tumor detection techniques, such as Ga labeled radionucleotide therapies and radiofrequency ablation technique. This trend is expected to support growth of the target market over the forecast period.
Rising manufacturers’ preference toward developing new NET drugs and improving clinical approach for neuroendocrine tumors treatment is expected to create potential revenue opportunities for players operating in the target market over the forecast period.
Global Neuroendocrine Tumor Treatment Market: Segment Analysis
Among end user, the hospitals segment is expected to register significant growth in terms of revenue over the forecast period, owing to availability of possible healthcare facilities.
Among indication, the gastrointestinal NET segment is expected to account for highest growth rate over the forecast period, owing to increasing prevalence of gastrointestinal NET among people across the globe.
Global Neuroendocrine Tumor Treatment Market: Regional Analysis
The market in North America is expected to dominate in the global market in terms of revenue over the forecast period, owing to technological advancements in therapies and approval of new drugs across various countries in the region. In addition, increasing strategic collaboration, acquisition, and merger activities by manufacturer operating in the target market in order to enhance their portfolio is another factor expected to support growth of the target market in this region over the forecast period.
The market in Asia pacific is expected to witness significant growth in terms of revenue over the forecast period, owing to increasing incidence of gastrointestinal neuroendocrine neoplasms and suitable regulatory environment for drugs used in treatment of neuroendocrine tumors across various countries in the region.
Global Neuroendocrine Tumor Treatment Market Segmentation:
Segmentation by drug:
- Sunitinib Malate
Segmentation by indication:
- Gastrointestinal NET
- Lung NET
- Pancreatic NET
- Others NET
Segmentation by end user:
- Oncology Centers
- Others (GI centers, Cardio-thoracic centers, NET centers)
Segmentation by region:
- North America
- Asia Pacific
- Latin America
- Middle East & Africa
Attribute Report Details Market Size Ask For Market Size Growth Rate Ask For Growth Rate Key Companies Ask For Companies Report Coverage Revenue analysis, Competitive landscape, Key company analysis, Market Trends, Key segments, Distribution Channel, Market Dynamics, COVID-19 Impact Analysis and more… Historical Data Period 2015-2020 Base Year 2022 Forecast Period 2022-2031 Region Scope North America, Europe, Asia-Pacific, South America, Middle East & Africa Country Scope United States, Canada and Mexico, Germany, France, UK, Russia and Italy, China, Japan, Korea, India and Southeast Asia, Brazil, Argentina, Colombia etc.Saudi Arabia, UAE, Egypt, Nigeria and South Africa Revenue in US$ Mn
- Pfizer Inc.
- Novartis AG
- Ipsen S.A.
- Advanced Accelerator Applications S.A.
- Tarveda Therapeutics, Inc.
- Progenics Pharmaceuticals, Inc.
- Hutchison MediPharma Limited
- Dauntless Pharmaceuticals, Inc.
- Exelixis, Inc.
- Chiasma, Inc.
Request for TOC
Don't just take our word. We are trusted by these great companies!